Drug intelligence / Profile preview

conjugated linoleic acid

Development stage: Phase 2
Lead developer: Dartmouth Hitchcock Medical Center
Modality: Small Molecules
Administration: Oral

Overview

Conjugated linoleic acid (CLA) is a naturally occurring fatty acid and dietary supplement being investigated for its potential antineoplastic effects in advanced solid tumors. In a clinical study led by Dartmouth-Hitchcock Medical Center, CLA (specifically the Clarinol formulation) was evaluated for its ability to inhibit lipid metabolism, a process critical for the survival and proliferation of certain cancer cells. The mechanism of action involves the suppression of S14 (Spot 14) expression, a protein that plays a key role in de novo fatty acid synthesis. By blocking the uptake and production of lipids, CLA aims to starve tumor cells and inhibit their growth.

Brand names: Clarinol
Other names: CLA

Targets

THRSP (Thyroid hormone responsive)

Beyond the preview

Go deeper on conjugated linoleic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on conjugated linoleic acid.

Explore the full profile